ClinicalTrials.gg
Status unknownNCT05576402Updated Dec 28, 2022

Endoscopic Scoring System Utilization in Inflammatory Bowel Disease

An observational study in Inflammatory Bowel Diseases, sponsored by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno. Status unknown at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Study summary

Inflammatory bowel diseases comprise two distinctive entities: Crohn's disease and ulcerative colitis. During the last decade, endoscopic assessment of inflammation has become relevant since it is a prognostic factor. As a consequence, therapeutic targets now contemplate mucosal healing as part of the goals to be achieved. Endoscopic scores for Crohn's disease and ulcerative colitis have been developed to objectively assess the mucosal inflammatory activity. Although they may have some limitations, these scores have been widely accepted in referral centers, especially since they have been adopted as standard evaluation in inflammatory bowel disease clinical trials . However, their use in the setting of endoscopic practice outside centers with a high volume or with less experience in clinical trials is not known.

02

Conditions studied

  • Inflammatory Bowel Diseases
03

In context

Inflammatory Bowel Diseases

1,487 studies on the registry are indexed under Inflammatory Bowel Diseases; 434 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 146 across 659 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients who have already received a diagnosis of either Crohn's disease or ulcerative colitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who underwent colonoscopy for the evaluation of mucosal inflammatory activity
  • Patients with an established diagnosis of either Crohn's disease or ulcerative colitis

Exclusion criteria

Exclusion Criteria:

  • Sigmoidoscopies performed in ulcerative colitis for the assessment of mucosal inflammatory activity
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,500 participants (estimated)
Patient registry
No

Interventions

  • Procedurecolonoscopy

    endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis

    Also known as: endoscopic score assessment

06

What researchers measure

Primary outcomes

  1. Endoscopic score report

    Proportion of colonoscopy reports among inflammatory bowel disease patients which include an endoscopic score to assess inflammatory activity

    Time frame: January 2018-October 2022

07

Study locations

1 of 1 sites recruiting
  • CEMIC
    Buenos Aires, 1425, Argentina
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05576402
Lead sponsor
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Responsible party
Juan Lasa (Principal investigator, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno) — Principal investigator
First posted
Oct 12, 2022
Start date
May 2, 2022
Primary completion
Jan 31, 2023 (estimated)
Completion
Feb 20, 2023 (estimated)
Last update
Dec 28, 2022

Study contacts

Juan S Lasa, MD
Contact
juanselasa@gmail.com
541140848182
Juan S Lasa, MD
principal investigator · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion